We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 136

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 1 2013

The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the

Leave to amend Statement of Defence denied

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 18 2011

Shire brought a motion seeking leave to amend its Statement of Defence to add a new defence of infringement as well as a defence of failure to mitigate

Antibody patent found valid and infringed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 27 2014

The Court recently decided a patent infringement case dealing with antibodies. The claims at issue in AbbVie’s patent relate to the use of a human

Court grants motion to reopen trial and admit new evidence

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 27 2011

The Federal Court granted leave to reopen the trial and admit new evidence in a matter under reserve, in which no reasons or judgement have issued

NOC proceeding dismissed on the basis of overbreadth and a lack of sound prediction

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 13 2013

In this case, one claim of a patent was at issue in the proceeding. The claim related to the use of pregabalin or its racemate to treat pain. The

Court dismisses NOC proceeding for mootness when NOA withdrawn

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 30 2013

Lilly brought an application for prohibition pursuant to the Patented Medicines (Notice of Compliance) Regulations. Subsequently, Teva established to

Appeal is neither stayed nor expedited

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 28 2011

The Court of Appeal was considering two motions, one motion by Mylan seeking to expedite the appeal, and one motion by AstraZeneca seeking to stay the appeal until the decision of the Supreme Court of Canada (SCC) in Teva Canada Limited v. Pfizer Canada Inc

Costs awarded seven years after discontinuance

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • December 21 2010

This decision relates to a motion brought by Bayer for an order for costs of an application brought pursuant to the Patented Medicines (Notice of Compliance) Regulations

Eli Lilly Canada v. Novopharm Limited

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • August 4 2010

The Court of Appeal overturned the decision of the trial judge which held that the patent was invalid

Court of Appeal upholds decision to deny amendments to statement of defence in Section 8 proceeding Sanofi-Aventis Canada Inc. v. Teva Canada Limited, 2014 FCA 65

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 24 2014

This appeal was heard in the context of an action commenced by Teva Canada Limited (“Teva”) seeking compensation from Sanofi-Aventis Canada Inc. and